Immun checkpoint inhibitor kombineret med pemetrexed intrathecal injektion til leptomeningeal metastase fra faste tumorer
Immun checkpoint inhibitor kombineret med pemetrexed intrathecal injektion til leptomeningeal metastase fra faste tumorer: en fase I/II undersøgelse
This is an open-label, single-arm, phase I/II trial of immune checkpoint inhibitor combined with pemetrexed intrathecal injection for leptomeningeal metastasis from solid tumors.
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Detaljeret beskrivelse
This is an open-label, single-arm, phase I/II trial of immune checkpoint inhibitor combined with pemetrexed intrathecal injection for leptomeningeal metastasis from solid tumors. The primary objective was to assess recommended dose and safety based on adverse events (AEs). All participants were observed to evaluate the clinical response rate (CRR), disease control rate (DCR) and overall survival (OS). Patients underwent cerebrospinal fluid (CSF) and blood specimen collection to evaluate potential clinical, molecular, and/or immune predictors of treatment efficacy and safety.
Undersøgelsestype
Undersøgelsestype
Tilmelding (Faktiske)
Tilmelding
Fase
Fase
- Fase 2
- Fase 1
Kontakter og lokationer
Studiesteder
-
-
-
Beijing, Kina, 101100
- Beijing Chest Hospital, Capital Medical University
-
Beijing, Kina
- Cancer Center, Aerospace Center Hospital, Peking University Aerospace School of Clinical Medicine
-
Shanghai, Kina
- Jinshan Hospital, Fudan University
-
-
Guangdong
-
Huizhou, Guangdong, Kina, 516000
- The Affiliated Huizhou Hospital, Guangzhou Medical University
-
Huizhou, Guangdong, Kina
- Huizhou First Hospital Affiliated to Guangdong Medical University
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Histologically or cytologically confirmed diagnosis of solid tumors; Cerebrospinal fluid cytopathology is positive.
- Male or female aged between 18 and 75 years; Normal liver and kidney function; WBC≥4000/mm3, Plt≥100000/mm3.
- No history of severe nervous system disease; No severe dyscrasia.
Exclusion Criteria:
- Any evidence of nervous system failure, including severe encephalopathy, grade 3 or 4 leukoencephalopathy on imaging, and Glasgow Coma Score less than 11.
- Any evidence of extensive and lethal progressive systemic diseases without effective treatment.
- A history of HIV or AIDS, active hepatitis B or C infection, previous anti-PD1 therapy-induced pneumonitis, or have ongoing >Grade 2 adverse events of such therapy; or ongoing autoimmune disease that required systemic treatment in the past 2 years.
- Patients with poor compliance or other reasons that were unsuitable for this study.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: Group
Immune checkpoint inhibitor combined with pemetrexed |
Drug 1: Toripalimab 40 mg; Drug 2: pemetrexed 15mg. intrathecal injection therapy |
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Recommended dose
Tidsramme: The dose limiting toxicity will be evaluated during the first 6 weeks of study treatment (the DLT window).
|
The recommended dose of intrathecal PD-1 inhibitor. The dose limiting toxicity was defined as ≥ grade 3 neurological toxicities (e.g., chemical meningitis) or other grade 4 toxicity. |
The dose limiting toxicity will be evaluated during the first 6 weeks of study treatment (the DLT window).
|
|
Incidence of treatment-related adverse events
Tidsramme: From date of treatment until discontinuation of study treatment.
|
The incidence of treatment-related adverse events were measured for determining tolerability and safety. Adverse events (AEs) are evaluated according to the Common Terminology Criteria for Adverse Events (CTCAE). Events of grade 3-5 are defined as moderate and severe adverse events. |
From date of treatment until discontinuation of study treatment.
|
Andre resultatmål
Andre resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Clinical response rate
Tidsramme: From date of treatment until the date of first documented progression or date of death from any cause, whichever came first.
|
The response assessment in neuro-oncology criteria (RANO) proposal for response criteria of leptomeningeal metastasis was used to assess the clinical response in this study. |
From date of treatment until the date of first documented progression or date of death from any cause, whichever came first.
|
|
Progression-free survival related to leptomeningeal metastasis (LMPFS)
Tidsramme: From enrollment to LM progression or death, whichever occurred first, or the last follow-up (at least 7 months).
|
LMPFS was defined as time from the enrollment until leptomeningeal metastasis progression or death, whichever occurred first. The leptomeningeal metastasis progression was determined based on the RANO proposal evaluation criteria which have been established and published on Neuro Oncol. |
From enrollment to LM progression or death, whichever occurred first, or the last follow-up (at least 7 months).
|
|
Overall survival(OS)
Tidsramme: From the enrollment of this study until date of death from any cause, whichever came first, or the last follow-up (at least 7 months).
|
Survival time was recorded since the date of patient enrollment. All patients were followed up until death or the end of the study. |
From the enrollment of this study until date of death from any cause, whichever came first, or the last follow-up (at least 7 months).
|
|
Disease control rate
Tidsramme: From date of treatment until the date of first documented progression or date of death from any cause, whichever came first.
|
Disease control rate is defined as the proportion who achieve an leptomeningeal metastasis response or stable disease. |
From date of treatment until the date of first documented progression or date of death from any cause, whichever came first.
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Samarbejdspartnere
Samarbejdspartnere
Publikationer og nyttige links
Generelle publikationer
- Pan Z, Yang G, Cui J, Li W, Li Y, Gao P, Jiang T, Sun Y, Dong L, Song Y, Zhao G. A Pilot Phase 1 Study of Intrathecal Pemetrexed for Refractory Leptomeningeal Metastases From Non-small-cell Lung Cancer. Front Oncol. 2019 Aug 30;9:838. doi: 10.3389/fonc.2019.00838. eCollection 2019.
- Glitza Oliva IC, Ferguson SD, Bassett R Jr, Foster AP, John I, Hennegan TD, Rohlfs M, Richard J, Iqbal M, Dett T, Lacey C, Jackson N, Rodgers T, Phillips S, Duncan S, Haydu L, Lin R, Amaria RN, Wong MK, Diab A, Yee C, Patel SP, McQuade JL, Fischer GM, McCutcheon IE, O'Brien BJ, Tummala S, Debnam M, Guha-Thakurta N, Wargo JA, Carapeto FCL, Hudgens CW, Huse JT, Tetzlaff MT, Burton EM, Tawbi HA, Davies MA. Concurrent intrathecal and intravenous nivolumab in leptomeningeal disease: phase 1 trial interim results. Nat Med. 2023 Apr;29(4):898-905. doi: 10.1038/s41591-022-02170-x. Epub 2023 Mar 30.
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Sygdomme i nervesystemet
- Neoplasmer efter sted
- Neoplasmer
- Neoplasmer i nervesystemet
- Meningeale neoplasmer
- Neoplasmer i centralnervesystemet
- Meningeal karcinomatose
- Aminosyrer, peptider og proteiner
- Heterocykliske forbindelser
- Heterocykliske forbindelser, 2-ring
- Heterocykliske forbindelser, smeltet ring
- Guanine
- Hypoxanthines
- Purinoner
- Puriner
- Glutamater
- Aminosyrer, sur
- Aminosyrer
- Aminosyrer, dicarboxylic
- Pemetrexed
- Toripalimab
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- TPLM
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
All individual participant data that underlie results in a publication will be available to other researchers.
IPD-delingstidsramme
Starting 6 months after publication
IPD-delingsadgangskriterier
Individual participant data will be public accessable via contacting with principal investigator by email within 6 months after the trial complete
IPD-deling Understøttende informationstype
- STUDY_PROTOCOL
- SAP
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .